Valuation: Royalty Pharma plc

Market Cap 25.48B 22.07B 20.57B 18.92B 35.72B 2,423B 36.12B 242B 94.88B 1,212B 95.7B 93.59B 4,015B P/E 2026 *
21.7x
P/E 2027 * 17x
Enterprise Value 34.63B 30B 27.96B 25.72B 48.55B 3,293B 49.09B 329B 129B 1,648B 130B 127B 5,457B EV / Sales 2026 *
9.98x
EV / Sales 2027 * 9.3x
Free-Float
71.97%
Yield 2026 *
1.74%
Yield 2027 * 1.83%
1 day+0.12%
1 week-2.38%
Current month-1.13%
1 month+1.49%
3 months+14.53%
6 months+31.00%
Current year+49.51%
1 week 56.36
Extreme 56.36
59.67
1 month 54.95
Extreme 54.95
60.44
Current year 38.29
Extreme 38.29
60.44
1 year 34.08
Extreme 34.0805
60.44
3 years 24.05
Extreme 24.05
60.44
5 years 24.05
Extreme 24.05
60.44
10 years 24.05
Extreme 24.05
60.44
Manager TitleAgeSince
Chief Executive Officer 62 01/01/1996
Director of Finance/CFO 44 01/01/2010
Chief Tech/Sci/R&D Officer - 21/09/2023
Director TitleAgeSince
Chairman 62 01/04/2020
Director/Board Member 68 11/02/2020
Director/Board Member 63 16/06/2020
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Sell

Executive/Senior Manager

-9,099 0.0021%
30/06/26 Sell

Executive/Senior Manager

-130,000 0.0293%
30/06/26 Free

Director

689 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
+0.17%-2.38%+52.39%+87.44% 25.48B
+3.77%-3.97%+51.70%+155.89% 995B
+1.25%-2.57%+51.53%+49.46% 614B
+0.42%-6.74%+23.68%+63.35% 431B
+1.96%+0.83%+42.80%+37.70% 353B
-0.11%-4.07%+30.37%+38.52% 293B
+2.52%-8.36%+7.27%+10.56% 245B
+3.15%+4.10%+34.48%+59.54% 210B
-4.32%-12.94%-3.79%-46.07% 210B
-3.11%-1.04%+16.80%+62.82% 168B
Average +0.60%-4.93%+30.72%+51.92% 354.37B
Weighted average by Cap. +1.49%-5.88%+36.59%+72.12%

Financials

2026 *2027 *
Net sales 3.47B 3B 2.8B 2.58B 4.86B 330B 4.92B 32.92B 12.92B 165B 13.03B 12.74B 547B 3.74B 3.24B 3.02B 2.78B 5.24B 356B 5.3B 35.49B 13.93B 178B 14.05B 13.74B 589B
Net income 1.65B 1.43B 1.34B 1.23B 2.32B 157B 2.34B 15.69B 6.16B 78.69B 6.21B 6.07B 261B 2.06B 1.78B 1.66B 1.53B 2.89B 196B 2.92B 19.54B 7.67B 98B 7.74B 7.57B 325B
Net Debt 9.15B 7.93B 7.39B 6.8B 12.83B 870B 12.98B 86.84B 34.08B 435B 34.38B 33.62B 1,442B 9.33B 8.08B 7.53B 6.92B 13.07B 887B 13.22B 88.47B 34.72B 444B 35.02B 34.25B 1,469B
Logo Royalty Pharma plc
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. It collaborates with innovators from academic institutions, research hospitals and non-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta and Alyftrek, Johnson & Johnson’s Tremfya, GSK’s Trelegy, Roche’s Evrysdi, Servier’s Voranigo, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, and Gilead’s Trodelvy, among others, and 20 development-stage product candidates.
Employees
100
Date Price Change Volume
05/08/26 $57.75 +0.47% 1,782,518
04/08/26 $57.48 +0.54% 3,684,203
03/08/26 $57.17 -2.16% 2,747,780
31/07/26 $58.43 -1.00% 2,156,928
30/07/26 $59.02 -0.27% 2,846,336
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
57.48USD
Average target price
61.62USD
Spread / Average Target
+7.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RPRX Stock